Home / Health / Cholesterol Drug Shows Alzheimer's Prevention Potential
Cholesterol Drug Shows Alzheimer's Prevention Potential
13 Jul
Summary
- Obicetrapib significantly reduces Alzheimer's biomarker p-tau217.
- Drug shows promise for Alzheimer's prevention in APOE4 gene carriers.
- New study may highlight APOE4 testing's benefit in Alzheimer's.
NewAmsterdam's experimental cholesterol-lowering therapy, obicetrapib, has shown promising results in reducing a key biomarker associated with Alzheimer's disease. Data from a sub-study of the Phase III BROADWAY trial revealed that obicetrapib significantly lowered levels of p-tau217 in patients carrying the APOE4 gene, a genetic factor known to elevate the risk of developing Alzheimer's.
The drug's impact was most pronounced in patients with two copies of the APOE4 gene, showing a substantial reduction in p-tau217 levels compared to those receiving a placebo. This targeted effect supports the hypothesis that obicetrapib may compensate for APOE4-related lipid transport issues, rather than providing a general benefit.
These findings, presented at the Alzheimer's Association International Conference in London, underscore a significant gap in the coordinated care of cardiovascular and neurological conditions. The company's CEO, Michael Davidson, stated that obicetrapib's potential to prevent both vascular strokes and Alzheimer's dementia could revolutionize preventative strategies.
Building on these results, NewAmsterdam plans to launch the SPINOZA trial to further investigate obicetrapib's efficacy in high-risk patients. This upcoming study will incorporate learnings from the BROADWAY trial and include an open-label extension, offering all participants the drug.
